Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Elena Vargas-Accarino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hepatitis C, Hepatitis B, Hepatitis D. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Gilead Sciences.
Abstract (Originalsprache)
Background
The WHO has set a goal to decrease viral hepatitis‐related fatalities by 65% by 2030.
Aims
To locate and retrieve to care all individuals diagnosed with hepatitis B, D or C, and investigate why they were not linked to appropriate medical management.
Methods
We conducted a retrospective‐prospective search for patients with hepatitis B, D or C virus (HBV, HDV and HCV) infection in the central laboratory database of the Barcelona northern health area (catchment population, 450,000). We reviewed records and contacted candidates for retrieval who were offered a specialist medical visit.
Results
We reviewed records of 3731 patients with viral hepatitis (January 2019–December 2022): 1763 HBsAg+, 69 anti‐HDV+ and 1899 HCV‐RNA+. Among these, 644 (37%) HBV, 20 (29%) HDV and 1116 (56%) HCV patients were not currently linked to care. The proportion of patients receiving appropriate care was higher in HBV and HDV ( p < 0.0001), and a higher percentage of unlinked hepatitis C patients had low life expectancy/comorbidities (39%; p < 0.0001). After implementing the linkage strategy, 254 HBV, 16 HDV and 54 HCV patients were successfully reintegrated into care. Among 1780 patients requiring linkage, 638 (35.8%) had moved to another health area or were missing essential contact data.
Conclusions
Among patients with viral hepatitis who required appropriate specialist care and were eligible for contact, 64% with HBV, 100% with HDV and 27% with HCV were successfully reintegrated into care. Overall, 324 (47.2%) eligible patients were linked to care, indicating the success of this strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Liver Diseases Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
- Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
- CIBERehd, enfermedades hepáticas y digestivas, Madrid, Spain.
- Hepatology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
ORCID-Profile: Elena Vargas-Accarino, Juan Carlos Ruiz-Cobo, Mar Riveiro-Barciela
Förderung
- Instituto de Salud Carlos III
- Gilead Sciences
Zitieren
APA
Vargas-Accarino, E., Rando-Segura, A., Palom, A., Feliu-Prius, A., Martínez-Campreciós, J., Barreira, A., Romero-Vico, J., Ruiz-Cobo, J. C., Llaneras, J., Riveiro-Barciela, M., Rodríguez-Frías, F., Esteban, R., & Buti, M. (2024). Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18227
Vancouver
Vargas-Accarino E, Rando-Segura A, Palom A, Feliu-Prius A, Martínez-Campreciós J, Barreira A, et al. Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18227
BibTeX
@article{VargasAccarino2024,
author = {Vargas-Accarino, Elena and Rando-Segura, Ariadna and Palom, Adriana and Feliu-Prius, Anna and Martínez-Campreciós, Joan and Barreira, Ana and Romero-Vico, Judit and Ruiz-Cobo, Juan Carlos and Llaneras, Jordi and Riveiro-Barciela, Mar and Rodríguez-Frías, Francisco and Esteban, Rafael and Buti, María},
title = {Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18227}
}
EUVIMED